Cyril Pillai Background.  Generative artificial intelligence (AI) is increasingly used for de novo design of small-molecule drug candidates, with the promise of accelerating early discovery and therapeutic targets1,2. However, many studies still define success using computational metrics such as novelty, validity, docking scores, and predicted drug-likeness, which do not directly…